Medical Industry Feature   /     Digital Therapeutics Clinical Trials: From Design to Data Interpretation

Subtitle
Duration
00:00:00
Publishing date
2024-11-22 00:00
Link
https://reachmd.com/programs/medical-industry-feature/digital-therapeutics-clinical-trials-from-design-to-data-interpretation/16210/
Contributors
Enclosures
https://reachmd.com/programs/medical-industry-feature/digital-therapeutics-clinical-trials-from-design-to-data-interpretation/16210/podcast/53065.mp3?partner=itunes
audio/mpeg

Shownotes

Host: Charles Turck, PharmD, BCPS, BCCCP
Guest: Sarah Shizuko Morimoto, PsyD

Digital therapeutics are a rapidly developing type of treatment option across several therapeutic areas, including mental health. And while the technology is advancing rapidly, the science behind it needs time to catch up, so it’s important to evaluate the supporting evidence when considering digital therapeutics for mental health.1 Joining Dr. Charles Turck to share her insights on how we can assess digital therapeutics is Dr. Sarah Shizuko Morimoto, Associate Professor of Population Health Sciences at the University of Utah in Salt Lake City.

Reference:

  1. American Psychiatric Association. Accessed July 3, 2024. https://www.psychiatry.org/psychiatrists/practice/mental-health-apps/the-app-evaluation-model

Dr. Morimoto is a paid consultant of Otsuka.

November 2024 US.UNB.X.24.00100